As the pharmaceutical industry evolves away from a blockbuster-based market, will it be ready for a more-personalized, almost-consumerized approach uniting traditional pharma with biotechnology and user-centered drug delivery?
Peter Schmitt and Frank Bieganousky, managing directors of Montesino Associates, plan to uncover the answer to that question and more at Pharmapack North America in the panel discussion, “What’s Next for Pharma” on June 9.
There’s no question that change is here. “When I think of pharmaceutical packaging, a quote from Winston Churchill comes to mind: ‘Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning,’ ” cites Schmitt.
The healthcare system is evolving into a more patient-focused, outcomes-oriented system, so payers more and more are expecting measurable—and cost-effective—results from pharmaceutical therapies. Patients continue to struggle with medication adherence, however. What can pharma companies do to help ensure positive patient outcomes, as they themselves face unprecedented changes in competition and the supply chain? What roles can packaging and drug-delivery devices play in encouraging patient adherence and wellness?
Schmitt wonders whether change will happen through disruption rather than evolution. He also asks whether such change will originate from outside of the pharma industry.
Bieganousky wonders whether some pharmaceutical companies might be turning to outsourcing and partnerships to increase their chances of developing an effective package.
Joining Schmitt and Bieganousky for the panel discussion will be Siong Ho, senior director, packaging science & technology, Shire; Jim Powers, senior director of package engineering for Teva Pharmaceuticals, and Walter Berghan, Executive Director, Healthcare Compliance Packaging Council.
Get ready for a conversation about where market forces and new discoveries will push pharma packaging. Come with provocations and insights and help shape your future. Please register here.
